NWPF

News ArchivesRead News

Your Weekly Parkinson's News Update for the Week of 12.24.18

Monday December 24, 2018
IBM Researchers Monitor Parkinson’s with Fingernail Sensors
Venture Beat
Grip strength can reveal a lot about a person, including whether Parkinson's is about to set in and how far it has progressed. "In a study published in the journal Scientific Reports, researchers from IBM describe a wearable system — a 'fingernail sensor' — that measures how a person’s fingernail bends and moves continuously (a key indicator of grip strength), and machine learning models that can derive health state insights from those metrics."
Certain Types of Requip (Parkinson's Treatment)
Soon to Be Discontinued
FDA via EMPR
The FDA has posted a discontinuation notice for Requip (ropinirole HCl; GlaxoSmithKline) tablets and certain Requip XL (ropinirole HCl; GlaxoSmithKline) extended-release tablets. 
"The affected products include Requip 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg, and 5mg strength tablets in 100-count bottles, and Requip XL 2mg strength tablets in 30-count bottles. The anticipated final dates of availability to patients are as follows:
  • Requip 0.25mg (NDC 0007-4890-20): April 2019
  • Requip 0.5mg (NDC 0007-4891-20): May 2019
  • Requip 1mg (NDC 0007-4892-20): January 2019
  • Requip 2mg (NDC 0007-4893-20): January 2019
  • Requip 3mg (NDC 0007-4895-20): April 2019
  • Requip 4mg (NDC 0007-4896-20): May 2019
  • Requip 5mg (NDC 0007-4894-20): March 2019
  • Requip XL 2mg (NDC 0007-4885-13): March 2019
The discontinuation of these products was a business decision, according to the FDA notice. Requip XL is still available as 4mg, 6mg, 8mg, and 12mg extended-release tablets." 
Parkinson's Experts Devise a Roadmap for Studies, Trials
EurekAlert!
A recently discovered protein, alpha-synuclein, has become one of the most attractive targets for developing new drugs with the potential to slow down or arrest the progression of Parkinson's. Experts in the field of Parkinson's research have now proposed a roadmap for preclinical and clinical trials that will investigate compounds targeting alpha-synuclein, published in The Journal of Parkinson's Disease.
Correction:
The previous Weekly offered the incorrect summary for an article titled
Chinese Medicinal Formula Shows Success
in Models of Parkinson’s
See below for an accurate summary:
Motor deficits seen in the Parkinson's mouse model were prevented with Optimized Yinxieng Formula (OYF) treatment. This study suggests that OYF can be used as an effective anti-inflammatory treatment in Parkinson's mouse model, providing a novel perspective for the treatment and prevention of Parkinson's, although more studies of clinical trials in Parkinson's might be necessary.